Sanofi to Seek U.S. Approval for First Dengue Vaccine in Months
- Vaccine has been cleared in 11 nations including Thailand
- Drugmaker expects to launch vaccine in Indonesia, Costa Rica
This article is for subscribers only.
Sanofi plans to seek U.S. approval for its dengue vaccine as early as this year after reaching the market in parts of Latin America and Asia where the mosquito-borne infection is widespread.
The French drugmaker is focusing on the most vulnerable countries before bringing the vaccine, called Dengvaxia, to more developed regions, with a goal of getting the product on the market in about 30 nations from Malaysia to Colombia, Guillaume Leroy, dengue vice president at Sanofi’s vaccines unit, said in an interview Tuesday.